ShapiroE.D.Prophylaxis for bacterial meningitis.Med Clin North Am.1985; 69: 269–280.
2.
SandeM.A., MandellG.L.Effect of rifampin on nasal carriage of Staphylococcus aureus.Antimicrob Agents Chemother.1975; 7: 294–297.
3.
WheatJ.L., KohlerR.B., LuftF.C.Long-term studies of the effect of rifampin on nasal carriage of coagulasepositive staphylococci.Rev Infect Dis.1983; 5(Suppl 3): S459–S462.
4.
TuazonC.U., LinM.Y.C., SheagrenI.N.In vitro activity of rifampin alone and in combination with nafcillin and vancomycin against pathogenic strains of Staphylococcus aureus.Antimicrob Agents Chemother.1978; 13: 759–761.
5.
WatanakunakornC., GuerrieroJ.C.Interaction between vancomycin and rifampin against Staphylococcus aureus.Antimicrob Agents Chemother.1981; 19: 1089–1091.
6.
TraczewskiM.M., GoldmannD.A., MurphyP.In vitro activity of rifampin in combination with oxacillin against Staphylococcus aureus.Antimicrob Agents Chemother.1983; 23: 571–576.
7.
TofteR.W., SollidayJ., RotschaferJ.Staphylococcus aureus infection of dialysis shunt: Absence of synergy with vancomycin and rifampin.South Med J.1981; 74: 612–615.
8.
MandellG.L.The antimicrobial activity of rifampin: Emphasis on the relation to phagocytes.Rev Infect Dis.1983; 5(Suppl 3): S463–S467.
9.
BuggyB.P., SchabergD.R., SwartzR.D.Intraleukocytic sequestration as a cause of persistent Staphylococcus aureus peritonitis in continuous ambulatory peritoneal dialysis.Am J Med.1984; 76: 1035–1040.
DoughertyS.H.Infections in the bionic man.Pharmaco therapy.1988; 8: 7S–10S.
13.
ObstG., GagnonR.F., PrentisJ.Rifampin activity against Staphylococcus epidermidis biofilms.Trans Am Soc Artif Intern Organs.1988; 34: 782–784.
14.
ObstG., GagnonR.F., PrentisJ.Modulation of antibiotic activity against Staphylococcus epidermidis biofilms by therapeutic drugs added to peritoneal dialysis (PD) solutions.Kidney Int.1989; 35: 274.
15.
AbrahamG., SavinE., AyiomamitisA.Natural history of exit-site infection in patients on continuous ambulatory peritoneal dialysis.Perit Dial Int.1988; 8: 211–216.
16.
ZimmermanS.W., O'BrienM., WiedenhoeftF.A.Staphylococcus aureus peritoneal-catheter related infections: A cause of catheter loss and peritonitis.Perit Dial Int.1988; 8: 191–194.
17.
MortonA.R., WalderS., HolmesA.M.Management of exit-site infections during continuous ambulatory peritoneal dialysis.Lancet.1987; 1: 1258.
18.
SewellC.M., ClarridgeJ., LackeC.Staphylococcal nasal carriage and subsequent infection in peritoneal dialysis patients.JAMA.1982; 248: 1493–1495.
19.
AhrensE.R., ZimmermanS.W., LeggettJ.Increased incidence of exit-site infections in CAPD patients with nasal carriage of Staphylococcus aureus.Kidney Int.1988; 33: 243.
20.
LuzarM.A., ColesG.A., FallerB.CAPD S. aureus nasal carriage-A link to infection.Perit Dial Int.1989; 9(Suppl 1): 105.
21.
YuV.L., GoetzA., WagenerM.Staphylococcus aureus nasal carriage and infection in patients on hemodialysis.N Engl J Med.1986; 315: 91–96.
SofferO., NassarV.H., CampbellW.G.Light chain cast nephropathy and acute renal failure associated with rifampin therapy.Am J Med.1987; 82: 1052–1056.
24.
American Thoracic Society.Treatment of tuberculosis and tuberculosis infection in adults and children.Am Rev Respir Dis.1986; 134: 355–363.
25.
BaciewiczA.M., SelfT.H., BekemeyerW.B.Update on rifampin drug interactions.Arch Intern Med.1987; 147: 565–568.
26.
JonkmanJ.H.Therapeutic consequences of drug interactions with theophylline pharmacokinetics.J Allergy Clin Immunol.1986; 78: 736–742.
27.
BarbarashR.A., BaumanJ.L., FischerJ.H.N ear total reduction in verapamil bioavailability by rifampin. Electrocardiographic correlates.Chest.1988; 94: 954–959.
28.
TsuchihashiK., FukamiK., KishimotoH.A case of variant angina exacerbated by administration of rifampicin.Heart Vessels.1987; 3: 214–217.
29.
BaciewiczA.M., SelfT.H.Rifampin drug interactions.Arch Intern Med.1984; 144: 1667–1671.
